Background: Chronic kidney disease (CKD) is associated with poor outcomes after percutaneous coronary intervention (PCI). The aim of the study was to compare zotarolimus-and everolimus-eluting stents used during primary PCI in patients with acute myocardial infarction (AMI) and CKD. Methods: We selected 854 consecutive ST-elevation MI patients with CKD (estimated glomerular filtration rate <60 mL/min/1.73 m 2 ) undergoing primary PCI who were followed up for 12 months. They were divided into two groups based on type of stents implanted: (1) zotarolimus-eluting stent (ZES) and (2) everolimus-eluting stent (EES). The study end point was the 12-month major adverse cardiac events (MACE) which included all-cause death, non-fatal MI, target lesion revascularization (TLR), and target vessel revascularization (TVR). Results: The average number of stents used per vessel was 1.4 ± 0.7. A total of 433 patients received ZES and 421 patients received EES. There was no significant difference in the incidence of 12-month MI, TLR, or TVR. All-cause death was found to be borderline significant between two groups (2.8% in ZES vs 0.9% in EES, p = 0.05). The incidence of 12-month MACE in ZES and EES was 5.7% and 2.6% respectively, p = 0.022. Stent thrombosis did not differ between groups (p = 0.677). Kaplan-Meier analysis did not show significant difference for 12-month MACE-free survival between groups (log-rank p = 0.158). It remained the same even after propensity adjustment for multiple confounders in Cox model (p = 0.326). Conclusions: Implantation of ZES or EES provided comparable clinical outcomes with similar risk of 12month MACE and death in STEMI patients with CKD undergoing primary PCI.
Introduction
Patients with chronic kidney disease (CKD) present with accelerated atherosclerosis and higher cardiovascular morbidity and mortality [1] [2] [3] . Furthermore, CKD is associated with adverse outcome following percutaneous coronary intervention (PCI) [4, 5] , likely related to endothelial dysfunction, inflammation, and platelet activation. After PCI with bare metal stents (BMS), the need for repeat revascularization remains high [6] , although the http://dx.doi.org/10.1016/j.jjcc.2014.02.002 0914-5087/© 2014 Published by Elsevier Ltd on behalf of Japanese College of Cardiology. restenosis rate in mild to moderate CKD is not increased at 9 months [7] . Retrospective analyses have demonstrated that, in the intermediate term, despite a higher overall mortality and morbidity after PCI, patients with end-stage renal disease [8] as well as those with milder degrees of CKD [9] benefit from lower rates of target vessel revascularization (TVR) with drug-eluting stent (DES) versus BMS placement. Despite the high prevalence of coronary artery disease among CKD patients, this patient population has been consistently excluded from the major clinical trials in cardiovascular medicine [10] .
We sought to investigate which of the most commonly used stents best suit patients with moderate to severe CKD undergoing primary PCI. We compared 12-month the clinical outcomes in two types of stents.
Methods
This is a retrospective study that was carried out in the Heart Center of Chonnam National University Hospital, Gwangju, Korea. The permission to carry out the study was obtained from the hospital authorities (Institutional Review Board number 05-49, I-2008-01-009) and written informed consent was taken from all patients.
Korea Acute Myocardial Infarction Registry
The Korea Acute Myocardial Infarction Registry is a prospective, multicenter, observational registry designed to examine current epidemiology in hospital management and the outcome of patients with acute myocardial infarction (AMI) in Korea for the commemoration of the 50th anniversary of the Korean Circulation Society. The registry included 52 community and university hospitals for primary PCI with 1-year clinical follow-up. Data were collected at each site by a well-trained study coordinator based on a standardized protocol [11] .
Study population
Patients were enrolled in the registry after admission to participating hospitals with a suspected diagnosis of AMI. Patients' medical documents were used to note the demographic data, clinical characteristics, and relevant laboratory results.
A total of 854 consecutive patients with ST-segment elevation MI with CKD undergoing primary PCI from April 2006 through September 2010 were selected in this study. We studied their 12-month clinical outcomes (follow-up rate was 100%). CKD was defined as estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 calculated using the Modification of Diet in Renal Disease (MDRD) method [12] . Patients on hemodialysis or continuous ambulatory peritoneal dialysis, with cardiogenic shock and evidence of heart failure were excluded from this study. They were divided into two groups based on the type of stents implanted -zotarolimus-eluting stents (ZES, n = 433, endeavor = 369 and resolute = 64; Medtronic CardioVascular, Santa Rosa, CA, USA), and everolimus-eluting stents (EES, n = 421).
Definitions and clinical endpoints
A final diagnosis of AMI was made according to the European Society of Cardiology/American College of Cardiology (ACC) diagnostic criteria of AMI [13] . Hypertension was defined as systolic blood pressure >140 mmHg and/or diastolic blood pressure >90 mmHg at rest, at repeated measurements or treatment with anti-hypertensive medications. Diabetes was defined as having an established diagnosis of diabetes mellitus or use of oral hypoglycemic agent or insulin to lower blood glucose levels. Hyperlipidemia was defined as a total cholesterol level >200 mg/dL or treatment with a lipid-lowering agent. Coronary artery disease was defined as history of MI, revascularization procedure, or obstructive coronary artery disease.
Peripheral blood samples were obtained using direct venipuncture. Blood samples were centrifuged and serum was removed and stored at a temperature of −70 • C until the assay could be performed for proteins and sugar. Absolute creatine kinase-MB levels were determined by radioimmunoassay (Dade Behring, Inc., Miami, FL, USA). Cardiac specific troponin I levels were measured by a paramagnetic particle, chemiluminescent immunoenzymatic assay (Beckham, Coulter, Inc., Fullerton, CA, USA). Twelve-hour fasting serum levels of total cholesterol, triglyceride, and low-and high-density lipoprotein cholesterol were measured by standard enzymatic methods. Blood samples for high-sensitivity C-reactive protein (CRP) were obtained on admission and analyzed turbidimetrically with sheep antibodies against human CRP; this has been validated against the Dade Behring method.
Two-dimensional echocardiography was performed in all patients and left ventricular ejection fraction was assessed using modified Simpson's biplanar method. The morphology in coronary angiography was classified according to the criteria of ACC/American Heart Association (AHA) [14] . Degree of coronary flow was classified by Thrombolysis In Myocardial Infarction (TIMI) score [15] . Renal function was assessed by eGFR, which was calculated using the MDRD method [12] . teh presence of left main coronary artery stenosis was defined as a luminal stenosis ≥50%. Multivessel disease was defined as the presence of a lesion with >50% diameter stenosis in a non-infarct related coronary artery. Successful PCI was defined as TIMI flow three with residual stenosis ≤50% in the infarct-related artery. Inhospital complications included any of atrio-ventricular block, bradycardia, ventricular tachycardia/ventricular fibrillation, atrial fibrillation, cardiogenic shock, no re-flow, dissection, acute renal failure, metabolic acidosis/lactic acidosis, cerebrovascular event, or infection/sepsis. All patients were administered loading doses of aspirin 325 mg and clopidogrel 300-600 mg before PCI. Anticoagulation during PCI was performed according to the routine practices of each hospital. After the procedure, aspirin 100-300 mg (once per day) was prescribed indefinitely. Clopidogrel was prescribed continuously for 1 year to patients who underwent DES implantation.
The clinical endpoint of this study was the major adverse cardiac events (MACE) which included all-cause death, non-fatal myocardial infarction (MI), target lesion revascularization (TLR) and TVR during the 12-month follow-up. Non-fatal MI was defined as the presence of clinical symptoms, electrocardiographic change, or abnormal imaging findings of MI combined with an increase in creatine kinase-MB fraction or troponin T/I more than the 99th percentile of the upper normal limit that was not related to an interventional procedure. TVR defined as clinically driven repeat revascularization of a lesion in the same epicardial vessel treated in the index procedure at 12-month follow-up. TLR was defined as any revascularization of the target lesion due to restenosis or re-occlusion within 5 mm proximal/distal to the stent. All data were recorded on a standardized, electronic, web-based registry at http://www.kamir.or.kr.
Statistical analysis SPSS 17.0 for windows (SPSS, Inc., Chicago, IL, USA) was used for all analysis. Continuous variables were presented as mean ± standard deviation; comparisons were conducted by Student's t-test. Discrete variables were presented as percentages and frequencies; comparisons were conducted by chi-square statistics. A p-value <0.05 was considered statistically significant. Kaplan-Meier curves were constructed to examine the incidence of clinical endpoints. Cox proportional hazard analysis was performed to identify a model with independent predictive factors with determination of a hazard ratio and its 95% confidence interval for each variable in the model. Covariates included in the model were age, stent length, pre-procedure TIMI flow grade 0, creatinine kinase-MB, and the use of thrombus aspiration device. As the number of 12-month MACE was relatively small in our study population, we limited the variables into the model. The results are presented as adjusted hazard ratios with 95% confidence intervals and p-values. We performed propensity score matching to enable an even more rigorous adjustment for selection biases and confounding factors.
Results
A total of 854 consecutive patients with AMI and CKD undergoing PCI were included in the present study. The average age of the total population was 64.1 ± 12.7 years and 81.6% were men. The mean stent length was 23.0 ± 6.5 mm and the mean stent diameter was 3.2 ± 0.5 mm. The average number of stents used per vessel was 1.4 ± 0.7.
Baseline clinical and laboratory characteristics and concomitant medications
Baseline clinical and laboratory characteristics and concomitant medications of the two groups are presented in Table 1 . Patients in the ZES group were older with lower heart rate, higher prevalence of family history of coronary artery disease, and higher serum level of creatinine kinase-MB. Use of calcium-channel blockers and fibrates was less frequently observed in the ZES group compared to that in the EES group.
Coronary angiographic and procedural characteristics
Coronary angiographic characteristics and procedural results of the two groups are presented in Table 2 . Patients in the ZES group had higher pre-PCI TIMI grade 0 flow, larger stent length, and higher use of thrombus aspiration device compared to the EES group. Other coronary angiographic characteristics did not show statistically meaningful differences between the two groups.
Twelve-month clinical outcomes
The 12-month clinical outcomes are presented in Table 3 . The incidence of 12-month MACE was higher in the ZES group compared to that in the EES group (5.7% vs 2.6%) and the incidence of all-cause death was higher in ZES with borderline significance compared to EES (2.8% vs 0.9%). It is however noteworthy that non-fatal MI, TVR, TLR, and stent thrombosis were not statistically significantly different between groups. A total of five cases of stent thromboses developed of which two were sub-acute (one in ZES, one in EES) and three were late stent thromboses (two in ZES, one in EES). The average rate of PCI success was 98.3%. Kaplan-Meier survival analysis demonstrated insignificant differences in freedom from MACE and death between two groups (Fig. 1) . Cox proportional hazard analysis revealed no statistical differences in the incidence of MACE and death when adjusted for multiple confounders. MACE and all-cause death at 12 months did not differ significantly between the two groups despite propensity score adjustment using Cox model, p = 0.326 for MACE, p = 0.569 for death ( Fig. 2 ). Subgroup analysis stratified by eGFR below 30 mL/min/1.73 m 2 or above 30 mL/min/1.73 m 2 was performed. This was analyzed by using Cox regression model adjusted by propensity score. The results are presented in the forest plot as shown in Fig. 3 . This did not show any significant differences in 12-month MACE between ZES and EES either in eGFR >30 mL/min/1.73 m 2 or <30 mL/min/1.73 m 2 subgroups.
Discussion
The present study demonstrates that implantation of ZES or EES provided comparable clinical outcomes with similar risk of 12month MACE and death in STEMI patients with CKD undergoing primary PCI.
Most studies of cardiovascular outcomes have found that a breakpoint for the development of contrast-induced nephropathy, acute or subacute stent thrombosis, later restenosis, recurrent myocardial infarction, diastolic/systolic congestive heart failure, and cardiovascular death occurs below an eGFR of 60 mL/min/1.73 m 2 , which roughly corresponds to a serum creatinine level higher than 1.5 mg/dL in the general population [16] [17] [18] . A study by Bonello et al. [19] showed a graded increase in serious in-hospital complications (death, vascular complications, need for transfusion, acute renal failure, MACE), 1-month events (death, repeat MI, TLR, MACE), and 1-year outcomes (death, MI, TLR, MACE) as renal function declined. In spite of these poor outcomes, use of PCI is associated with superior long-term survival when compared with medical therapy alone in the management of acute coronary syndrome in CKD patients [20] . The frequency of clinical adverse events was also higher according to the stages of CKD. Hachinohe et al. [21] demonstrated when patients with non-ST segment elevation MI have severe CKD, the conservative or deferred invasive strategy with prescription of cardio-protective medication and prevention of further deterioration in renal function should be considered. They demonstrated that early invasive strategy was superior to deferred invasive strategy in mild CKD patients. However, this tendency decreased as renal function decreased and deferred strategy was superior to early invasive strategy in severe CKD patients.
Although the use of new interventional devices, including stents, improved immediate procedural success rates, CKD patients also had higher long-term mortality rates (27.7% versus 6.1%, p < 0.0001) than patients with normal renal function [22] . There are several leading explanations for CKD being such a potent risk factor for adverse outcomes: (a) excess co-morbidities in CKD patients, including older age and diabetes; (b) underused end-organ protective strategies in CKD patients, or therapeutic nihilism; (c) excess toxicities from conventional therapies used including radiocontrast material and antithrombotic agents; and (d) the unique pathobiology of the CKD state, which includes intrarenal vasoconstriction when exposed to iodinated contrast agents [23] .
Coronary stents have substantially improved the efficacy of percutaneous revascularization. Use of DES has further reduced the rates of in-stent restenosis and repeat revascularization compared to BMS [24] . Despite the widespread use of DES in treating coronary artery disease which is prevalent among end-stage renal disease patients, the safety and efficacy of DES in this population have not been well defined. The overall results of a meta-analysis including 869 patients by Abdel-Latif et al. [25] indicate that DES use in these patients is safe and results in a modest yet statistically significant reduction in adverse clinical events. Importantly, the procedural success with DES was similar to that encountered with BMS. DES use significantly reduced the risk of TLR/TVR and MACE, but did not significantly influence the risk of all-cause mortality or MI. A study by Serruys et al. [26] demonstrated that at 13 months, the new-generation ZES was found to be non-inferior to the EES in the general population. Our study showed that either of the two commonly used stents can be used to treat AMI patients with CKD (eGFR <60 mL/min/1.73 m 2 ) undergoing primary PCI, with similar risk of 12-month MACE. DESs have significantly reduced rates of restenosis compared to BMS, but an increased risk of late stent thrombosis has emerged as a major concern [27]. However, we observed no significant between-group difference in overall rates of stent thrombosis. Our observations may be influenced by selection bias and residual confounding or may represent a true finding; it is at least hypothesis-generating that needs to be further evaluated using a long-term randomized controlled study.
